Reach Us +44 1202068036

Ovation: The Sealing O Ring New Concept

Paulo Eduardo Ocke Reis*

Department of Specialized and General Surgery, Fluminense Federal University, Rio de Janeiro, Brazil

*Corresponding Author:
Paulo Eduardo Ocke Reis
Department of Specialized and General Surgery
Fluminense Federal University, Rio de Janeiro, Brazil.
Tel: +55 21 2629-5000
E-mail: [email protected]

Received date: March 14, 2016; Accepted date: April 19, 2016; Published date: April 22, 2016

Citation: Reis PEO. Ovation: The Sealing O-Ring–New Concept. J Vasc Endovasc Surg. 2017, 2:18. doi: 10.21767/2573-4482.100050

Visit for more related articles at Journal of Vascular and Endovascular Therapy


In 1991, Dr. Juan Parodi described, for the first time, the exclusion of an Abdominal Aortic Aneurism (AAA) from circulation using an endovascular approach. He showed that a perfect seal zone between the endograft and the aortic wall was necessary to completely exclude the AAA [1]. Today, Endovascular Aneurysm Repair (EVAR) has replaced open surgical repair as the most common method of treatment for AAA. Controlled trials, including the EVAR Trial 1, one and two year results and the DREAM trial 30 day results, have shown early benefits of EVAR versus open repair in the treatment of AAA, however, the total mortality benefit was lost after two years [2].

Authors agree that complex proximal neck anatomy represents one of the most common contraindications for commercially available devices, complications such as type I endoleaks, kinking, and migration could be related with aortic sac rupture and death [2-6]. Additionally, enlargement of the infrarenal aortic neck has been reported after EVAR interventions [7]. Though EVAR can be used in patients with short aortic necks, it is associated with type I endoleaks as found in Aburahma et al. [8].

The Ovation® Abdominal Stent Graft System (Ovation System) (Endologix Inc., Santa Rosa, Calif) (Figure 1) is a recently approved trimodular bifurcated device that has a new concept of sealing, using polymer based technology to create a patient specific sealing O-Ring. The Ovation System is comprised of a main body and two limbs which are delivered via a flexible hydrophilic 13F–14F OD catheter. The aortic body consists of a low permeability Polytetrafluoroethylene (PTFE) graft, and suprarenal nitinol stent with integral anchors; and the iliac limbs are made of nitinol stents encapsulated in PTFE. Once in the appropriate location the Ovation System is deployed in stages. First the graft is fixated in the intended location by deploying the suprarenal anchors and then a patient specific seal is achieved in situ by introducing a low viscosity, radiopaque fill polymer through a network of inflatable channels and sealing rings that cures to the native anatomy of the aorta (Figure 2) [9,10]. The kink-resistant iliac limbs are then deployed on both the ipsilateral and contralateral side to complete the deployment. The Ovation System improves the viability and efficient of EVAR by its ability to treat a wide range of anatomies including difficult anatomies for traditional EVAR [9-11]. Women with AAA, who typically have smaller diameter access vessels, more calcified tortuous iliac vessels, and short aortic necks, may be particularly well suited for the Ovation Systems low profile delivery system that can help “navigate” small diameters access vessels and complex anatomy [9]. A sub-analysis of the Ovation Multicenter Post Market Registry demonstrated that through three year women derived similar benefit to men with EVAR intervention using the Ovation System [9].


Figure 1: The Ovation® abdominal stent graft platform is FDAapproved to the complex aortoilac aneurismatic disease.


Figure 2: The sealing ring technology exerts no chronic outward force and insulates the neck from blood pressure. Patients treated with the Ovation Platform in the pivotal study had no neck dilatation and no late type 1 endoleaks at 3 years.

There is strong clinical evidence to support the long term durability of the Ovation System’s polymer based sealing O-Ring. For example, the results of De Donato et al. paper on the multicenter registry of patients treated with the Ovation endograft, showed that at three years, that there was no aneurysm-related death, rupture, stent–graft migration, or neck enlargement [12].

Furthermore, the effectiveness of the Ovation System was consistent for patients with short neck lengths defined as <7 mm compared to patients with longer aortic necks of ≥7 mm long both groups showing continuous wall apposition with a circumferential non-expansive seal independent of aortic neck length. These results showed that the use of the Ovation System is not restricted by the conventional measurement of aortic neck length, affirming the recent Food and Drug Administrationapproved changes to the device-specific instructions for use to require an aortic neck inner wall diameter between 16 and 30 mm at 13 mm below the inferior renal artery instead of the traditional neck length requirement [12].

The Ovation System’s sealing O-Ring-new concept is characterized by non-expansive circumferential apposition of polymer-filled rings to aortic wall creating no chronic out-ward force at the infrarenal aortic level. The mechanism for achieving seal is completely different from that obtained by self-expanding stent grafts, with no morphologic changes to isolate the aortic wall neck from blood pressure, thus preventing aortic constantly changing over time (Figure 3) [13].


Figure 3: Aortic neck segmentation into three zones: Zone A: Suprarenal aorta/fixation area; Zone B: Infrarenal aorta, from lowest renal artery to the first polymer-filled ring; and Zone C: Infrarenal aorta, at level of the first polymerfilled ring/sealing zone.

Additional evidence of the clinical utility of the Ovation Systems O-Ring was shown by Mehta et al. presentation of the 5 year results of the Global Pivotal Trial Data during the, 2016, Veith Symposium [14]. The Ovation Pivotal Trial included a total of 161 patients, enrolled in Chile, Germany and USA from November 2009 to December 2011. Through five years, the key highlights from the data included [14]:

• Broad patient applicability, with 40% of the patients treated outside the labeled indications of other Endovascular Aortic Repair (EVAR) devices.

• Stable aortic neck diameters with an average expansion of 0.1%, compared to 25% as reported with other EVAR devices. 97.5% Freedom from secondary interventions related to type 1 endoleak.

• No migration or conversions.

Dr. Mehta commented, “The five-year data from the Ovation Pivotal Trial confirms the long-term safety and durability of the Ovation system. The study included the broadest range of AAA.” We are optimistic that the Ovation endograft is now a viable and safe option for treating patients with challenging aortic anatomies including short necks, as well as a solution to reduce the incidence of complications such as type I endoleaks, kinking, and migration which are related to aortic sac rupture and death.


Select your language of interest to view the total content in your interested language

Viewing options

Recommended Conferences
Post your comment

Share This Article

Flyer image

Post your comment

captcha   Reload  Can't read the image? click here to refresh